It was found that HNSC, SARC, and SKCM showed high performance of CDK4 and decreased overall survival time in all concerned skin tumors, while in disease-free survival, there was no significant difference between high performance and low performance in HNSC, but the overall prognosis of low performance was better than that of high performance, while the disease-free survival time of high performance of SARC and SKCM was less than that of low performance. This evidence concerns the gene CDK4 and skin neoplasm.